Loading clinical trials...
Loading clinical trials...
This Phase Ib/III study evaluates the efficacy and safety of IBI351 in combination with chemotherapy in advanced non-squamous NSCLC with KRAS G12C mutation.
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
Innovent Biologics (Suzhou) Co. Ltd.
NCT07668037 · Non-Small Cell Carcinoma of Lung, Immunotherapy, and more
NCT05482568 · Advanced Non-small Cell Lung Cancer
NCT07222566 · Advanced Non-Small Cell Lung Cancer, Non-Small Cell Lung Cancer, and more
NCT07528274 · NSCLC (Non-small Cell Lung Cancer), NSCLC (Advanced Non-small Cell Lung Cancer)
NCT07001618 · NSCLC (Advanced Non-small Cell Lung Cancer)
Jilin Province Cancer Hospital
Jilin City, Changchun
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions